Clal Biotechnology reported ILS14.69M in Current Assets for its fiscal quarter ending in December of 2023.





Current Assets Change Date
Arca Biopharma USD 395.25M 51.39M Mar/2026
aTyr Pharma USD 67.58M 178.23M Mar/2026
Bio Path USD 663K 17K Sep/2025
Brainstorm Cell Therapeutics USD 184K 123K Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 148.02M 59.1M Dec/2025
Immunic USD 188.76M 165.89M Mar/2026
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
RedHill Biopharma USD 12.56M 644K Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024